Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Neurosurg Psychiatry

Retrieve available abstracts of 76 articles:
HTML format



Single Articles


    January 2023
  1. TOOROP AA, Hogenboom L, Bloem K, Kocyigit M, et al
    Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jan 24:jnnp-2022-330793.
    PubMed     Abstract available


  2. AKERSTEDT T, Olsson T, Alfredsson L, Hedstrom AK, et al
    Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study.
    J Neurol Neurosurg Psychiatry. 2023 Jan 23:jnnp-2022-330123.
    PubMed     Abstract available


  3. SASTRE-GARRIGA J, Rovira A, Garcia-Vidal A, Carbonell-Mirabent P, et al
    Spinal cord reserve in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jan 23:jnnp-2022-330613.
    PubMed     Abstract available


  4. MENCULINI G, Mancini A, Gaetani L, Bellingacci L, et al
    Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction.
    J Neurol Neurosurg Psychiatry. 2023 Jan 18:jnnp-2022-329806.
    PubMed     Abstract available


  5. TOOROP AA, van Kempen ZLE, Steenhuis M, Nielsen J, et al
    Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jan 13:jnnp-2022-330467.
    PubMed     Abstract available


  6. SIGNORI A, Lorscheider J, Vukusic S, Trojano M, et al
    Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
    J Neurol Neurosurg Psychiatry. 2023;94:23-30.
    PubMed     Abstract available


    December 2022
  7. VAN KEMPEN ZLE, Stalman EW, Steenhuis M, Kummer LYL, et al
    SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Dec 23:jnnp-2022-330100.
    PubMed     Abstract available


  8. SMITH KA, Piehl F, Olsson T, Alfredsson L, et al
    Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study.
    J Neurol Neurosurg Psychiatry. 2022 Dec 20:jnnp-2022-329886.
    PubMed     Abstract available


  9. AIELLO A, Coppola A, Ruggieri S, Farroni C, et al
    Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
    J Neurol Neurosurg Psychiatry. 2022 Dec 15:jnnp-2022-330175.
    PubMed     Abstract available


  10. HE A, Spelman T, Manouchehrinia A, Ciccarelli O, et al
    Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study.
    J Neurol Neurosurg Psychiatry. 2022 Dec 7:jnnp-2022-330169.
    PubMed     Abstract available


    November 2022
  11. MONTALBAN X, Wallace D, Genovese MC, Tomic D, et al
    Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
    J Neurol Neurosurg Psychiatry. 2022 Nov 23:jnnp-2022-328799.
    PubMed     Abstract available


  12. DILWALI S, Mark I, Waubant E
    MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Nov 17. pii: jnnp-2022-330172.
    PubMed     Abstract available


  13. MARGONI M, Gueye M, Meani A, Pagani E, et al
    Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex.
    J Neurol Neurosurg Psychiatry. 2022 Nov 9. pii: jnnp-2022-330343.
    PubMed     Abstract available


  14. COMABELLA M, Tintore M, Sao Aviles A, Carbonell-Mirabent P, et al
    Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Nov 7. pii: jnnp-2022-330205.
    PubMed     Abstract available


  15. HARDING KE, Ingram G, Tallantyre EC, Joseph F, et al
    Contemporary study of multiple sclerosis disability in South East Wales.
    J Neurol Neurosurg Psychiatry. 2022 Nov 3. pii: jnnp-2022-330013.
    PubMed     Abstract available


  16. LUTFULLIN I, Eveslage M, Bittner S, Antony G, et al
    Association of obesity with disease outcome in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Nov 1. pii: jnnp-2022-329685.
    PubMed     Abstract available


    October 2022
  17. ZHU C, Zhou Z, Roos I, Merlo D, et al
    Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Oct 19. pii: jnnp-2022-330104.
    PubMed     Abstract available


  18. CAROTENUTO A, Valsasina P, Preziosa P, Mistri D, et al
    Monoaminergic network abnormalities: a marker for multiple sclerosis-related fatigue and depression.
    J Neurol Neurosurg Psychiatry. 2022 Oct 13. pii: jnnp-2022-330109.
    PubMed     Abstract available


  19. WEI R, Xu X, Duan Y, Zhang N, et al
    Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Oct 10. pii: jnnp-2022-329680.
    PubMed     Abstract available


    September 2022
  20. LANDI D, Bovis F, Grimaldi A, Annovazzi PO, et al
    Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Sep 30. pii: jnnp-2022-329657.
    PubMed     Abstract available


  21. SHARMIN S, Malpas CB, Roos I, Diouf I, et al
    Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.
    J Neurol Neurosurg Psychiatry. 2022 Sep 30. pii: jnnp-2022-329713.
    PubMed     Abstract available


  22. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study.
    J Neurol Neurosurg Psychiatry. 2022 Sep 28. pii: jnnp-2022-329854.
    PubMed     Abstract available


  23. WILLUMSEN JS, Grytten N, Aarseth J, Myklebust TA, et al
    Mortality and cause of death in multiple sclerosis in western Norway 1950-2021: a registry-based linkage study.
    J Neurol Neurosurg Psychiatry. 2022 Sep 12. pii: jnnp-2022-329169.
    PubMed     Abstract available


    August 2022
  24. MARRIE RA, Fisk JD, Walld R, Bolton JM, et al
    Prescription opioid use in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Aug 26. pii: jnnp-2022-329508.
    PubMed    


  25. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
    Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea.
    J Neurol Neurosurg Psychiatry. 2022 Aug 26. pii: jnnp-2022-329628.
    PubMed     Abstract available


  26. BOSE G, Healy BC, Barro C, Glanz BI, et al
    Younger age at multiple sclerosis onset is associated with worse outcomes at age 50.
    J Neurol Neurosurg Psychiatry. 2022 Aug 11. pii: jnnp-2022-329353.
    PubMed     Abstract available


  27. KVISTAD SAS, Burman J, Lehmann AK, Tolf A, et al
    Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
    J Neurol Neurosurg Psychiatry. 2022;93:844-848.
    PubMed     Abstract available


    July 2022
  28. CHEN J, Diouf I, Taylor BV, Kalincik T, et al
    Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329223.
    PubMed     Abstract available


  29. KWON S, Jung SY, Han KD, Jung JH, et al
    Risk of Parkinson's disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea.
    J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329389.
    PubMed     Abstract available


  30. LASLETT LL, Honan C, Turner JA, Dagnew B, et al
    Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life.
    J Neurol Neurosurg Psychiatry. 2022 Jul 27. pii: jnnp-2022-329227.
    PubMed     Abstract available


  31. ROD BE, Torkildsen O, Myhr KM, Bo L, et al
    Safety of breast feeding during rituximab treatment in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 25. pii: jnnp-2022-329545.
    PubMed     Abstract available


  32. MEYER-ARNDT L, Braun J, Fauchere F, Vanshylla K, et al
    SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
    J Neurol Neurosurg Psychiatry. 2022 Jul 14. pii: jnnp-2022-329395.
    PubMed     Abstract available


    June 2022
  33. ABDELHAK A, Cordano C, Boscardin WJ, Caverzasi E, et al
    Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 16. pii: jnnp-2022-329221.
    PubMed     Abstract available


  34. WANDALL-HOLM MF, Buron MD, Kopp TI, Thielen K, et al
    Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 10. pii: jnnp-2022-329058.
    PubMed     Abstract available


  35. ETEMADIFAR M, Nouri H, Pitzalis M, Idda ML, et al
    Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2022 Jun 10. pii: jnnp-2022-329123.
    PubMed     Abstract available


  36. LIE IA, Kacar S, Wesnes K, Brouwer I, et al
    Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study.
    J Neurol Neurosurg Psychiatry. 2022 Jun 1. pii: jnnp-2021-328568.
    PubMed     Abstract available


    May 2022
  37. MARGONI M, Pagani E, Meani A, Storelli L, et al
    Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study.
    J Neurol Neurosurg Psychiatry. 2022 May 17. pii: jnnp-2022-328908.
    PubMed     Abstract available


  38. SIMPSON-YAP S, Atvars R, Blizzard L, van der Mei I, et al
    Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia.
    J Neurol Neurosurg Psychiatry. 2022 May 16. pii: jnnp-2022-328932.
    PubMed     Abstract available


    April 2022
  39. COMABELLA M, Sastre-Garriga J, Carbonell-Mirabent P, Fissolo N, et al
    Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 29. pii: jnnp-2022-329020.
    PubMed     Abstract available


  40. PROSPERINI L, Lucchini M, Ruggieri S, Tortorella C, et al
    Shift of multiple sclerosis onset towards older age.
    J Neurol Neurosurg Psychiatry. 2022 Apr 27. pii: jnnp-2022-329049.
    PubMed     Abstract available


  41. SUGIYAMA A, Kuwabara S
    Microstructural changes in the normal appearance cerebral cortex of multiple sclerosis detected by an advanced diffusion MRI technique.
    J Neurol Neurosurg Psychiatry. 2022 Apr 25. pii: jnnp-2021-328089.
    PubMed    


  42. BRENTON JN, Lehner-Gulotta D, Woolbright E, Banwell B, et al
    Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits.
    J Neurol Neurosurg Psychiatry. 2022 Apr 13. pii: jnnp-2022-329074.
    PubMed     Abstract available


  43. MAGYARI M, Koch-Henriksen N
    Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 7. pii: jnnp-2022-328994.
    PubMed     Abstract available


  44. EID K, Torkildsen O, Aarseth J, Aalstad M, et al
    Association of adverse childhood experiences with the development of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Apr 4. pii: jnnp-2021-328700.
    PubMed     Abstract available


    March 2022
  45. WILLIAMS T, Mishra R, Bharkhada B, Shields A, et al
    Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study.
    J Neurol Neurosurg Psychiatry. 2022 Mar 10. pii: jnnp-2021-328340.
    PubMed    


    February 2022
  46. RAUBER S, Korsen M, Huntemann N, Rolfes L, et al
    Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
    J Neurol Neurosurg Psychiatry. 2022 Feb 22. pii: jnnp-2021-328197.
    PubMed     Abstract available


    January 2022
  47. MASUDA H, Mori M, Hirano S, Uzawa A, et al
    Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol Neurosurg Psychiatry. 2022;93:32-40.
    PubMed     Abstract available


    November 2021
  48. PREZIOSA P, Pagani E, Bonacchi R, Cacciaguerra L, et al
    In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI.
    J Neurol Neurosurg Psychiatry. 2021 Nov 19. pii: jnnp-2021-327803.
    PubMed     Abstract available


  49. NIJ BIJVANK J, Uitdehaag BMJ, Petzold A
    Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics.
    J Neurol Neurosurg Psychiatry. 2021 Nov 11. pii: jnnp-2021-327468.
    PubMed     Abstract available


    October 2021
  50. KONIG M, Lorentzen AR, Torgauten HM, Tran TT, et al
    Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
    J Neurol Neurosurg Psychiatry. 2021 Oct 20. pii: jnnp-2021-327612.
    PubMed     Abstract available


  51. MASUDA H, Mori M, Kuwabara S
    Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Oct 19. pii: jnnp-2021-326821.
    PubMed    


  52. SIMPSON-YAP S
    Relationships with MS not unique to relapsing-onset phenotypes.
    J Neurol Neurosurg Psychiatry. 2021;92:1029-1030.
    PubMed    


    September 2021
  53. TAYLOR BV
    Sequencing of and escalation paradigms for MS therapies: time for a rethink?
    J Neurol Neurosurg Psychiatry. 2021;92:913.
    PubMed    


    August 2021
  54. DI FILIPPO M, Cordioli C, Malucchi S, Annovazzi P, et al
    mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Aug 18. pii: jnnp-2021-327200.
    PubMed    


  55. MONSCHEIN T, Hartung HP, Zrzavy T, Barnett M, et al
    Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.
    J Neurol Neurosurg Psychiatry. 2021 Aug 5. pii: jnnp-2021-326839.
    PubMed    


  56. LOUAPRE C, Ibrahim M, Maillart E, Abdi B, et al
    Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2021 Aug 2. pii: jnnp-2021-326904.
    PubMed     Abstract available


    July 2021
  57. MARGONI M, Villani U, Finos L, Franciotta S, et al
    Neurite orientation dispersion and density imaging discloses early changes in the normal-appearing white matter in paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jul 16. pii: jnnp-2021-326355.
    PubMed    


  58. DUAN Y, Zhuo Z, Li H, Tian DC, et al
    Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    J Neurol Neurosurg Psychiatry. 2021;92:709-716.
    PubMed     Abstract available


    June 2021
  59. WANG C, Barton J, Kyle K, Ly L, et al
    Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
    J Neurol Neurosurg Psychiatry. 2021 Jun 29. pii: jnnp-2021-326164.
    PubMed     Abstract available


    May 2021
  60. HEDSTROM AK, Hillert J, Olsson T, Alfredsson L, et al
    Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 May 13. pii: jnnp-2020-325688.
    PubMed     Abstract available


    April 2021
  61. COLATO E, Stutters J, Tur C, Narayanan S, et al
    Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.
    J Neurol Neurosurg Psychiatry. 2021 Apr 20. pii: jnnp-2020-325610.
    PubMed     Abstract available


    March 2021
  62. HAIDER L, Chung K, Birch G, Eshaghi A, et al
    Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up.
    J Neurol Neurosurg Psychiatry. 2021 Mar 30. pii: jnnp-2020-325421.
    PubMed     Abstract available


  63. PFEUFFER S, Ruck T, Pul R, Rolfes L, et al
    Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
    J Neurol Neurosurg Psychiatry. 2021 Mar 12. pii: jnnp-2020-325304.
    PubMed     Abstract available


  64. HEDSTROM AK, Hillert J, Brenner N, Butt J, et al
    DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325676.
    PubMed     Abstract available


  65. MURPHY OC, Mukharesh L, Salazar-Camelo A, Pardo CA, et al
    Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325274.
    PubMed     Abstract available


    February 2021
  66. KOCH-HENRIKSEN N
    It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease.
    J Neurol Neurosurg Psychiatry. 2021 Feb 9. pii: jnnp-2020-325684.
    PubMed    


    January 2021
  67. BURON MD, Kalincik T, Sellebjerg F, Sorensen PS, et al
    Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324869.
    PubMed     Abstract available


  68. PREZIOSA P, Bouman PM, Kiljan S, Steenwijk MD, et al
    Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324391.
    PubMed    


    November 2020
  69. WIJBURG MT, Warnke C, McGuigan C, Koralnik IJ, et al
    Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications.
    J Neurol Neurosurg Psychiatry. 2020 Nov 23. pii: jnnp-2020-324534.
    PubMed     Abstract available


  70. CUNNIFFE N, Vuong KA, Ainslie D, Baker D, et al
    Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Nov 12. pii: jnnp-2020-324286.
    PubMed     Abstract available


  71. KEIR LHM, Breen DP
    REM sleep behaviour disorder in patients without synucleinopathy.
    J Neurol Neurosurg Psychiatry. 2020;91:1239-1240.
    PubMed    


    October 2020
  72. ZHUKOVSKY C, Sandgren S, Silfverberg T, Einarsdottir S, et al
    Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
    J Neurol Neurosurg Psychiatry. 2020 Oct 26. pii: jnnp-2020-323992.
    PubMed     Abstract available


  73. ANNUNZIATA P
    More time, more safety: is this the future optimal way for natalizumab treatment in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2020 Oct 21. pii: jnnp-2020-324032.
    PubMed    


  74. CHISARI CG, Grimaldi LM, Salemi G, Ragonese P, et al
    Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 14. pii: jnnp-2020-323472.
    PubMed     Abstract available


    June 2020
  75. BUTZKUEVEN H, Kappos L, Wiendl H, Trojano M, et al
    Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    J Neurol Neurosurg Psychiatry. 2020;91:660-668.
    PubMed     Abstract available


    May 2020
  76. PREZIOSA P, Rocca MA, Pagani E, Storelli L, et al
    Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    J Neurol Neurosurg Psychiatry. 2020;91:493-502.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: